These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36087547)

  • 1. Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study.
    Alattar RA; Abdalla S; Abdallah T; Kazman R; Qadmour A; Ibrahim T; Alhariri B; Shaar SH; Bajwa A; Alimam A; Qazi R; Ben Abid F; Daghfal J; Eldeeb A; Shukri K; Elsayed A; Rustom F; Alsamawi M; Abdelmajid A; Basulto MAP; Cobian AAR; Abukhattab M; Alkhal A; Almaslamani MA; Omrani AS
    J Infect Public Health; 2022 Oct; 15(10):1061-1064. PubMed ID: 36087547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
    Chavalertsakul K; Sutherasan Y; Petnak T; Thammavaranucupt K; Kirdlarp S; Boonsarngsuk V; Sungkanuparph S
    Int J Gen Med; 2024; 17():2163-2175. PubMed ID: 38770366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
    Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
    J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
    Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS
    Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Altebainawi AF; AlFaifi M; Nahari M; Almagthali A; Thabit AK; Alhajaji R; Alharbi R; Kahtani K; Alenazi AA; Alharbi A; Alghwainm MM; Alotaibi SM; Alghamdi YS; Alotaibi S; Alonazi SH; Almutairi JM; Vishwakarma R
    J Infect Public Health; 2023 Sep; 16(9):1492-1499. PubMed ID: 37355406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.
    Ikeda M; Okugawa S; Kashiwabara K; Moritoyo T; Kanno Y; Jubishi D; Hashimoto H; Okamoto K; Tsushima K; Uchida Y; Mitsumura T; Igari H; Tsutsumi T; Araoka H; Yatera K; Yamamoto Y; Nakamura Y; Otani A; Yamashita M; Wakimoto Y; Shinohara T; Adachi-Katayama M; Oyabu T; Kanematsu A; Harada S; Takeshita Y; Nakano Y; Miyazaki Y; Sakao S; Saito M; Ogura S; Yamasaki K; Kawasuji H; Hataji O; Inoue JI; Seto Y; Moriya K
    Int J Infect Dis; 2023 Mar; 128():355-363. PubMed ID: 36610659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
    Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
    PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favipiravir for symptomatic COVID-19: A nationwide observational cohort study.
    Doi Y; Ishihara T; Banno S; Ando M; Kondo M;
    J Infect Chemother; 2023 Feb; 29(2):150-156. PubMed ID: 36307058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial.
    Shinkai M; Tsushima K; Tanaka S; Hagiwara E; Tarumoto N; Kawada I; Hirai Y; Fujiwara S; Komase Y; Saraya T; Koh H; Kagiyama N; Shimada M; Kanou D; Antoku S; Uchida Y; Tokue Y; Takamori M; Gon Y; Ie K; Yamazaki Y; Harada K; Miyao N; Naka T; Iwata M; Nakagawa A; Hiyama K; Ogawa Y; Shinoda M; Ota S; Hirouchi T; Terada J; Kawano S; Ogura T; Sakurai T; Matsumoto Y; Kunishima H; Kobayashi O; Iwata S
    Infect Dis Ther; 2021 Dec; 10(4):2489-2509. PubMed ID: 34453234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
    Fujii S; Ibe Y; Ishigo T; Inamura H; Kunimoto Y; Fujiya Y; Kuronuma K; Nakata H; Fukudo M; Takahashi S
    J Infect Chemother; 2021 Jul; 27(7):1051-1057. PubMed ID: 33902990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
    Hanai Y; Yoshizawa S; Matsuo K; Uekusa S; Miyazaki T; Nishimura K; Mabuchi T; Ohashi H; Ishii Y; Tateda K; Yoshio T; Nishizawa K
    Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115640. PubMed ID: 35193798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.